Glycosylation of autoantibodies: Insights into the mechanisms of immune thrombocytopenia

Thrombosis and Haemostasis

Volumn 110, Issue 6, 2013, Pages 1259-1266

  Bakchoul, Tamam ^a,b   Walek, Kathrin ^a   Krautwurst, Annika ^a   Rummel, Mathias ^c   Bein, Gregor ^a,c   Santoso, Sentot ^a   Sachs, Ulrich J ^a,c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Animal model; Autoantibody; Complement; ITP; Thrombocytopenia

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C1Q ANTIBODY; GLYCAN; IMMUNOGLOBULIN G ANTIBODY; N ACETYL BETA GLUCOSAMINIDASE;

ANIMAL EXPERIMENT; ARTICLE; CELL DESTRUCTION; CELL ISOLATION; CELL PHAGOCYTOSIS; CELL SURVIVAL; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION TEST; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEGLYCOSYLATION; FLOW CYTOMETRY; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOPATHOLOGY; LASER MICROSCOPY; MONOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PURIFICATION; THROMBOCYTE; THROMBOCYTOPENIA;

ANIMAL MODEL; AUTOANTIBODY; COMPLEMENT; ITP; THROMBOCYTOPENIA;

ANIMALS; ASPARAGINE; AUTOANTIBODIES; BLOOD PLATELETS; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MANNOSYL-GLYCOPROTEIN ENDO-BETA-N-ACETYLGLUCOSAMINIDASE; MICE, INBRED NOD; MICE, SCID; PHAGOCYTOSIS; POLYSACCHARIDES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84888400305     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0294     Document Type: Article

References (35)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardisation of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-93.
2. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
3. Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113: 6511-6521.
4. McMillan R. The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura. Curr Hematol Rep 2005; 4: 160-165.
5. McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 2005; 81: 94-99.
6. Nugent D, McMillan R, Nichol JL, et al. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146: 585-596.
7. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123-1124.
8. Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46: S2-14.
9. Cines DB, Liebman HA. The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am 2009; 23: 1155-1161.
10. Kiefel V, Santoso S, Mueller-Eckhardt C. Serological, biochemical, and molecular aspects of platelet autoantigens. Semin Hematol 1992; 29: 26-33.
11. Tomer A, Koziol J, McMillan R. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated autoantibodies against platelet-specific receptors. J Thromb Haemost 2005; 3: 74-78.
12. McMillan R, Longmire RL, Tavassoli M, Armstrong S, Yelenosky R. In vitro platelet phagocytosis by splenic leukocytes in idiopathic thrombocytopenic purpura. N Engl J Med 1974; 290: 249-251.
13. Tsubakio T, Tani P, Curd JG, McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol 1986; 63: 293-300.
14. McKenzie SE, Taylor SM, Malladi P, et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999; 162: 4311-4318.
15. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-290.
16. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann NY Acad Sci 2012; 1253: 170-180.
17. Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant 2011; 16: 7-14.
18. Collin M, Shannon O, Bjorck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci USA 2008; 105: 4265-4270.
19. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
20. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010; 236: 265-275.
21. Ravetch JV, Luster AD, Weinshank R, et al. Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science 1986; 234: 718-725.
22. Liang SX, Pinkevych M, Khachigian LM, et al. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. Blood 2010; 116: 1958-1960.
23. Bakchoul T, Zollner H, Amiral J, et al. Anti-protamine-heparin antibodies: incidence, clinical relevance and pathogenesis. Blood 2013; 121: 2821-2827.
24. Bougie DW, Nayak D, Boylan B, et al. Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia. Blood 2010; 116: 3033-3038.
25. Najaoui A, Bakchoul T, Stoy J, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol 2012; 88: 167-174.
26. Kiefel V, Santoso S, Weisheit M, et al. Monoclonal antibody--specific immobilisation of platelet antigens (MAIPA): a new tool for the identification of plateletreactive antibodies. Blood 1987; 70: 1722-1726.
27. Kiefel V. The MAIPA assay and its applications in immunohaematology. Transfus Med 1992; 2: 181-188.
28. Bakchoul T, Boylan B, Sachs UJ, et al. Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia. Transfusion 2009; 49: 265-270.
29. Bakchoul T, Kubiak S, Krautwurst A, et al. Low-avidity anti-HPA-1a alloantibodies are capable of antigen-positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. Transfusion 2011; 51: 2455-2461.
30. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180-191.
31. White KD, Cummings RD, Waxman FJ. Ig N-glycan orientation can influence interactions with the complement system. J Immunol 1997; 158: 426-435.
32. Peerschke EI, Andemariam B, Yin W, et al. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 2010; 148: 638-645.
33. Banda NK, Wood AK, Takahashi K, et al. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum 2008; 58: 3081-3089.
34. Chapin J, Weksler B, Magro C, et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012; 157: 772-774.
35. Shapira I, Andrade D, Allen SL, et al. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012; 64: 2719-2723.